IMO Pashka change is as difficult for organizations as it is for people
<<<<<< If the studies were good enough for the FDA to clear, why not good enough for insurance companies? >>>>>>>
Similar to the NHS local CCGs refusing to authorize doctors to prescribe ActiPatch, an NHS approved medical device, insurance companies are slow to adopt new treatments.
Even with BIEL demonstrating how ActiPatch use would lower patient use of medical care and therefor save CCGs/Insurers money they resist. They have a business model set up around 'a drug for every problem' and are evidently satisfied with the results despite the side effects, one of those being 600,000 opioid deaths.
After one Clearance for eyelid surgery the FDA dragged their feet for 13 years before reclassifying ActiPatch from a Class 3 Device, life sustaining products, to the less regulated Class 2 Device. So the FDA also has a history of maintaining the status quo.
News 
Market Data 
Discover 
AI
